Skip navigation
  • 中文
  • English

DSpace CRIS

  • DSpace logo
  • Home
  • Organizations
  • Researchers
  • Research Outputs
  • Explore by
    • Organizations
    • Researchers
    • Research Outputs
  • Academic & Publications
  • Sign in
  • 中文
  • English
  1. NTU Scholars
  2. 醫學院
  3. 醫學系
Please use this identifier to cite or link to this item: https://scholars.lib.ntu.edu.tw/handle/123456789/582772
DC FieldValueLanguage
dc.contributor.authorYING-CHUN CHIENen
dc.contributor.authorLee, Yu Linen
dc.contributor.authorLiu, Po Yuen
dc.contributor.authorLu, Min Chien
dc.contributor.authorPEI-LAN SHAOen
dc.contributor.authorLu, Po Liangen
dc.contributor.authorCheng, Shu Hsingen
dc.contributor.authorLin, Chi Yingen
dc.contributor.authorWu, Ting Shuen
dc.contributor.authorYen, Muh Yongen
dc.contributor.authorWang, Lih Shinnen
dc.contributor.authorLiu, Chang Panen
dc.contributor.authorLee, Wen Senen
dc.contributor.authorShi, Zhi Yuanen
dc.contributor.authorChen, Yao Shenen
dc.contributor.authorWang, Fu Deren
dc.contributor.authorTseng, Shu Huien
dc.contributor.authorYU-HUI CHENen
dc.contributor.authorWANG-HUEI SHENGen
dc.contributor.authorLee, Chun Mingen
dc.contributor.authorChen, Yen Hsuen
dc.contributor.authorKo, Wen Chienen
dc.contributor.authorPO-REN HSUEHen
dc.date.accessioned2021-09-14T23:18:47Z-
dc.date.available2021-09-14T23:18:47Z-
dc.date.issued2021-09-01en
dc.identifier.issn22137165en
dc.identifier.urihttps://scholars.lib.ntu.edu.tw/handle/123456789/582772-
dc.description.abstractObjectives: The aim of this study was to investigate the trends in serotypes and in vitro antimicrobial susceptibility of Streptococcus pneumoniae causing adult invasive pneumococcal disease (IPD) to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics from 2017–2020 following implementation of the 13-valent pneumococcal conjugate vaccine (PCV-13) and during the COVID-19 (coronavirus disease 2019) pandemic. Methods: During the study period, 237 S. pneumoniae isolates were collected from non-duplicate patients, covering 15.0% of IPD cases in Taiwan. Antimicrobial susceptibility testing was performed using a Sensititre® system. A latex agglutination method (ImmuLex™ Pneumotest Kit) was used to determine serotypes. Results: Susceptibility rates were high for vancomycin (100%), teicoplanin (100%) and linezolid (100%), followed by ceftaroline (non-meningitis) (98.3%), moxifloxacin (94.9%) and quinupristin/dalfopristin (89.9%). MIC50 and MIC90 values of dalbavancin, telavancin, tedizolid, eravacycline and omadacycline were generally low. Non-vaccine serotype 23A was the leading cause of IPD across the adult age range. Isolates of serotype 15B were slightly fewer than those of PCV-13 serotypes in patients aged ≥65 years. The overall case fatality rate was 15.2% (36/237) but was especially high for non-PCV-13 serotype 15B (21.4%; 3/14). Vaccine coverage was 44.7% for PCV-13 and 49.4% for the 23-valent pneumococcal polysaccharide vaccine (PPSV-23), but was 57% for both PCV-13 and PPSV-23. Conclusion: The incidence of IPD was stationary after PCV-13 introduction and only dramatically decreased in the COVID-19 pandemic in 2020. The MIC50 and MIC90 values of dalbavancin, telavancin, tedizolid, eravacycline, omadacycline were generally low for S. pneumoniae causing adult IPD.en
dc.relation.ispartofJournal of Global Antimicrobial Resistanceen
dc.subjectAntimicrobial susceptibility | Case fatality rate | Pneumococcal vaccine | Serotype | Streptococcus pneumoniae | Taiwanen
dc.subjectAntimicrobial susceptibility; Case fatality rate; Pneumococcal vaccine; Serotype; Streptococcus pneumoniae; Taiwan-
dc.subject.otheraminoglycoside; antiinfective agent; dalbavancin; eravacycline; omadacycline; oxazolidinone derivative; tedizolid; teicoplanin; telavancin; tetracycline derivative; tetrazole derivative; adult; antibiotic resistance; clinical trial; epidemiology; human; multicenter study; pandemic; serotype; Streptococcus pneumoniae; Taiwan; Adult; Aminoglycosides; Anti-Bacterial Agents; COVID-19; Drug Resistance, Bacterial; Humans; Lipoglycopeptides; Oxazolidinones; Pandemics; SARS-CoV-2; Serogroup; Streptococcus pneumoniae; Taiwan; Teicoplanin; Tetracyclines; Tetrazoles-
dc.subject.other[SDGs]SDG3-
dc.titleNational surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017–2020en
dc.typejournal articleen
dc.identifier.doi10.1016/j.jgar.2021.07.005en
dc.identifier.pmid34289409en
dc.identifier.scopus2-s2.0-85112565494en
dc.identifier.urlhttps://api.elsevier.com/content/abstract/scopus_id/85112565494en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.contributor.orcid#NODATA#en
dc.relation.journalvolume26en
dc.relation.pageend316en
item.openairecristypehttp://purl.org/coar/resource_type/c_6501-
item.openairetypejournal article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextno fulltext-
Appears in Collections:醫學系
Show simple item record

WEB OF SCIENCETM
Citations

1
checked on Jun 26, 2022

Page view(s)

7
checked on Jun 19, 2022

Google ScholarTM

Check

Altmetric

Altmetric

Related Items in TAIR


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Sherpa Romeo網站查詢,以確認出版單位之版權政策。
    Please use Sherpa Romeo to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)
Build with DSpace-CRIS - Extension maintained and optimized by Logo 4SCIENCE Feedback